2014

Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic NSCLC with disease progression on or who are intolerant to crizotinib; mercaptopurine as a 20 mg/mL oral suspension for the treatment of acute lymphoblastic leukemia as part of a combination regimen; siltuximab for the treatment of patients with multicentric Castleman’s disease who are human immunodeficiency virus-negative and human herpesvirus-8-negative; ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia for whom fludarabine-based therapy is considered inappropriate; ramucirumab as a single agent in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma; ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukemia (ibrutinib was approved in 2013 for the treatment of mantle cell lymphoma); trametinib and dabrafenib for use in combination in the treatment of unresectable or metastatic BRAF V600E or V600K mutation metastatic melanoma.

2013

Crizotinib for ALK-positive advanced non-small cell lung cancer; ­ibrutinib and lenalidomide in the treatment of mantle cell lymphoma; obinutuzumab for use in combination with chlorambucil in the treatment of chronic lymphocytic leukemia; pertuzumab injection for use in combination with trastuzumab and docetaxel as neoadjuvant treatment for HER2-positive breast cancer; paclitaxel in combination with gemcitabine for first-line treatment of advanced adenocarcinoma of the pancreas; afatinib and erlotinib for the first-line treatment of EGFR exon 19 deletions or exon 21 substitution mutations metastatic non–small cell lung cancer; trametinib for BRAF V600E or V600K mutation advanced melanoma; ­dabrafenib for BRAF 600E mutation metastatic melanoma; ado-trastuzumab ­emtansine as a single agent in HER-2 positive advanced breast cancer patients who received prior therapy with trastuzumab and a taxane; doxorubicin hydrochloride liposome injection for advanced ovarian cancer and for AIDS-related Kaposi’s sarcoma; bevacizumab for use in combination with fluoropyrimide-irinotecan or fluoropyrimidine-oxaliplatin-based chemotherapy for metastatic colorectal cancer.